Patents by Inventor Thomas Edward Prisinzano

Thomas Edward Prisinzano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF DEMYELINATING DISEASES
    Publication number: 20230096920
    Abstract: The present invention relates generally to methods of using nalfurafine for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing multiple sclerosis (MS). Also disclosed is nalfurafine for use in treating and/or preventing MS as well as pharmaceutical compositions and unit dosage forms comprising nalfurafine for use for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing MS.
    Type: Application
    Filed: September 30, 2022
    Publication date: March 30, 2023
    Inventors: Thomas Edward Prisinzano, Bronwyn Maree Kivell, Anne Camille La Flamme
  • Treatment of demyelinating diseases
    Patent number: 11324742
    Abstract: The present invention relates generally to methods of using nalfurafine for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing multiple sclerosis (MS). Also disclosed is nalfurafine for use in treating and/or preventing MS as well as pharmaceutical compositions and unit dosage forms comprising nalfurafine for use for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing MS.
    Type: Grant
    Filed: July 23, 2020
    Date of Patent: May 10, 2022
    Assignees: Victoria Link Ltd., University of Kansas
    Inventors: Thomas Edward Prisinzano, Bronwyn Maree Kivell, Anne Camille La Flamme
  • TREATMENT OF DEMYELINATING DISEASES
    Publication number: 20210023074
    Abstract: The present invention relates generally to methods of using nalmefene for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing multiple sclerosis (MS). Also disclosed is nalmefene for use in treating and/or preventing MS as well as pharmaceutical compositions and unit dosage forms comprising nalmefene for use for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing MS.
    Type: Application
    Filed: March 7, 2019
    Publication date: January 28, 2021
    Inventors: Bronwyn Maree Kivell, Anne Camille La Flamme, Thomas Edward Prisinzano
  • TREATMENT OF DEMYELINATING DISEASES
    Publication number: 20210015813
    Abstract: The present invention relates generally to methods of using nalfurafine for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing multiple sclerosis (MS). Also disclosed is nalfurafine for use in treating and/or preventing MS as well as pharmaceutical compositions and unit dosage forms comprising nalfurafine for use for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing MS.
    Type: Application
    Filed: March 7, 2019
    Publication date: January 21, 2021
    Inventors: Bronwyn Maree Kivell, Anne Camille La Flamme, Thomas Edward Prisinzano
  • Kappa opioid receptor effectors and uses thereof
    Patent number: 9540375
    Abstract: The present invention is a selective kappa opioid receptor effector, or a pharmaceutically acceptable salt thereof, useful for treating ethanol use disorder withdrawal, anxiety and/or depression, schizophrenia, mania or post-traumatic stress disorder.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: January 10, 2017
    Assignees: University of Kansas, The Scripps Research Institute
    Inventors: Jeffrey Aube, Laura Bohn, Thomas Edward Prisinzano, Frank John Schoenen, Kevin J. Frankowski
  • KAPPA OPIOID RECEPTOR EFFECTORS AND USES THEREOF
    Publication number: 20160257685
    Abstract: The present invention is a selective kappa opioid receptor effector, or a pharmaceutically acceptable salt thereof, useful for treating ethanol use disorder withdrawal, anxiety and/or depression, schizophrenia, mania or post-traumatic stress disorder.
    Type: Application
    Filed: May 17, 2016
    Publication date: September 8, 2016
    Inventors: Jeffrey Aube, Laura Bohn, Thomas Edward Prisinzano, Frank John Schoenen, Kevin J. Frankowski
  • Kappa opioid receptor effectors and uses thereof
    Patent number: 9345703
    Abstract: The present invention is a selective kappa opioid receptor effector, or a pharmaceutically acceptable salt thereof, useful for treating ethanol use disorder withdrawal, anxiety and/or depression, schizophrenia, mania or post-traumatic stress disorder.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: May 24, 2016
    Assignees: University of Kansas, The Scripps Research Institute
    Inventors: Jeffrey Aube, Laura Bohn, Thomas Edward Prisinzano, Frank John Schoenen, Kevin John Frankowski
  • KAPPA OPIOID RECEPTOR EFFECTORS AND USES THEREOF
    Publication number: 20140371227
    Abstract: The present invention is a selective kappa opioid receptor effector, or a pharmaceutically acceptable salt thereof, useful for treating ethanol use disorder withdrawal, anxiety and/or depression, schizophrenia, mania or post-traumatic stress disorder.
    Type: Application
    Filed: September 14, 2012
    Publication date: December 18, 2014
    Applicants: The Scripps Research Institute, University of Kansas
    Inventors: Jeffrey Aube, Laura Bohn, Thomas Edward Prisinzano, Frank John Schoenen, Kevin John Frankowski